William Hagopian, M.D., Ph.D.
Dr. Hagopian focuses on research strategies to predict and prevent type 1 diabetes
William Hagopian, M.D., Ph.D., serves as PNDRI's Scientific Director and focuses on research strategies in immunology and molecular biology for predicting and preventing type 1 diabetes before clinical disease onset. These studies include screening over 140,000 Washington State newborns to a) determine what environmental factors trigger the disease in those with genetic susceptibility and b) develop and implement cost-effective strategies for population-based pediatric screening for preclinical diabetes prediction. Finally, Dr. Hagopian pursues several clinical trials to find low-toxicity immune therapies to interrupt the inappropriate autoimmune response that attacks and kills the insulin-producing pancreatic islet cells. In addition to their potential to prevent diabetes before the clinical onset, these studies may help newly diagnosed patients to preserve the remaining insulin producing cells, enabling better management of blood sugar.